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Background: Escherichia coli is the most common uropathogen involved in urinary tract infection (UTI). Virulence
of strains may differ, and may be enhanced by antimicrobial resistance and biofilm formation, resulting in increased
morbidity and recurrent infections. The aim of this study was to evaluate the in vitro biofilm forming capacity of
E. coli isolates from dogs with UTI, by using fluorescent in situ hybridization, and its association with virulence genes
and antimicrobial resistance.
Findings: The proportion of biofilm-producing isolates significantly increased with the length of incubation time
(P < 0.05). Biofilm production was significantly associated with fluoroquinolone resistance at all incubation time
points and was independent of the media used (P < 0.05). Biofilm production was not associated with cnf1, hly,
pap and sfa genes (P > 0.05), but was significantly associated with afa, aer and the β-lactamase genes (P < 0.05).
Conclusions: To the best of our knowledge, this is the first report showing significant association between biofilm
production and fluoroquinolone resistance in E. coli isolates from dogs with UTI. Biofilm formation may contribute
to UTI treatment failure in dogs, through the development of bacterial reservoirs inside bladder cells, allowing
them to overcome host immune defenses and to establish recurrent infections.
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Escherichia coli is the most common uropathogen in
urinary tract infections (UTI) of humans and animals,
being responsible for high morbidity and increased
health care costs [1-3]. These infections are usually con-
sidered acute and self-limiting, but recurrent clinical signs
are often observed [3]. E. coli UTI pathogenesis is similar
in dogs and humans, and dogs may serve as reservoirs of
uropathogenic E. coli (UPEC) strains that can be transmit-
ted to humans and other animals [2,4]. In fact, the human
highly virulent O25:ST131 uropathogenic clone was re-
cently found in a dog with chronic cystitis [5,6]. This fact
suggests a possible human-to-animal transmission.
In humans, it is well established that UPEC are able to
form biofilm structures within the bladder, forming bac-
terial reservoirs that allow infection persistence [7-10].
These structures are highly organized multicelular com-
plexes, characterised by adherent colonies surrounded
by a large exopolysaccharide matrix. Biofilm structures* Correspondence: moliveira@fmv.ulisboa.pt
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and phagocytosis, allowing their survival in hostile environ-
ments within the host [10]. Detection of biofilm-producer
strains is therefore relevant for the design of adequate
control measures for UPEC infections. Fluoroquinolones
are extensively used for UTI treatment, due to the high
concentration levels reached in the urinary tract and good
tissue concentrations [11]. The aim of this study was to
evaluate the in vitro biofilm-forming ability of E. coli iso-
lates from dog urinary tract infections, and its association
with virulence and β- lactamase antimicrobial resistance
genes, and with 2nd generation quinolones resistance.
Sixty-six E. coli isolates were used, from a collection of
bacterial isolates from dogs with UTI belonging to the
Faculty of Veterinary Medicine, University of Lisbon.
Isolates virulence factors had already been determined
by multiplex PCR and described by us: 57.6% (n = 38)
were positive for S fimbriae gene sfa; 1.5% (n = 1) for afim-
brial adhesion I gene afaI; 42.4% (n = 28) for haemolysin
gene hly; 40.9% (n = 27) for cytotoxic necrotizing factor I
gene cnfI; 34.8% (n = 23) for aerobactin gene aer; and
42.4% (n = 28) for pyelonephritis-associated pili gene papLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Biofilm production and virulence and β-lactamase genes presence in 66 E. coli isolates from dogs with urinary
infectionsa
Biofilm production Virulence genes Multiplex-PCR
Isolate TSB, 24 hours pap sfa afa hly cnf1 aer TEM SHV OXA AMP C CTX-M
5 Negative - + - - - - - - - - -
13 Negative - + - - - - - - - - -
21 Negative + + + + + - - - - - -
34 Negative - - - - - - - - - - -
36 Positive - - - - - - - - - - -
43 Negative - - - - - - - - - - -
78 Positive + - - - - + + - - + -
84 Positive - + - + + - - - - - -
88 Negative + + - + + - - - - - -
91 Negative - - - - - + + - - + -
95 Negative - - - - - + + - - + -
99 Positive - - - - - - - - - - -
109 Positive + + - + + - - - - - -
115 Positive - + - - - - - - - - -
125 Positive - - - - - - + - - + -
128 Negative - - - - - - - - - - -
133 Positive - + - - - - - - - - -
134 Positive - + - - - - - - - - -
138 Positive + - - - - + - - - - -
174 Negative - + - - - - - - - - -
179 Negative - + - - - - - - - - -
188 Negative - - - - - + + - - + -
194 Negative - - - - - + + - - + -
207 Negative + + - + + - - - - - -
209 Negative + + - + + + - - - - -
224 Negative - - - - - + + - - + -
226 Negative - - - - - + + - - + -
227 Positive - + - + + - - - - - -
237 Negative + + - + + + - + - + -
238 Positive + + - + + + - + - + -
239 Positive + + - + + + - + - + -
250 Negative + - - - - - + - - + -
251 Positive + + - + + - - - - - -
257 Negative + + - + + - + - - + -
258 Negative - - - - - - + - - + -
271 Positive - - - - - - + - - + -
274 Positive - - - - - + + - - + -
291 Positive + + - + + - + - - + -
304 Positive - + - - - - - - - - -
320 Negative - - - - - + + - - + -
325 Positive + + - - + + - - - - -
327 Positive + - - + + - - - - - -
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Table 1 Biofilm production and virulence and β-lactamase genes presence in 66 E. coli isolates from dogs with urinary
infectionsa (Continued)
347 Negative - + - + + + - - + + -
354 Positive - - - - - + - - + + -
372 Negative + + - + + - - - - - -
374 Negative + + - + + - - - - - -
386 Positive - - + + - - + - - + -
401 Positive + + - + + + - - - - -
403 Positive - + - - - - + - - + -
417 Negative - - - - - - - - - - -
443 Positive + + - + + - - - - - -
449 Positive - + - - - - - - - - -
457 Negative + + - + + - - - - - -
461 Positive + + - + + - - - - - -
483 Positive - + - - - - - - - - -
488 Negative + + - + + - - - - - -
505 Negative - - - - - + + - - + -
528 Positive - - - - - - - - - - -
531 Positive + + - + + + - - - - -
536 Positive - + - - - - - - - - -
539 Positive - - - - - + + - - + -
540 Positive + + - + + - - - - - -
553 Negative - - - - - - + - - + -
554 Positive + + - + + + - - - - -
560 Positive + + - + + - - - - - -
566 Negative + - - - - + - - - - -
Total (n=) 35 28 38 1 28 27 23 20 3 2 25 0
% 53.0 42.4 57.6 1.5 42.4 40.9 34.8 30.3 4.5 3.0 37.9 0
aVirulence and β-lactamase genes results are adapted from Féria et al. [12] and Pomba et al. [13]; + PCR positive result; − PCR negative result.
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ance has also been previously described by us: 19 isolates
were positive for blaTEM (28.8%), three for blaSHV (4.5%),
two for blaOXA-1 (3.0%) and six for ampC (9.1%) [13].
Minimum inhibitory concentrations (MIC) of ciproflox-
acin (CIP, Laboratório Atral-Cipan, Portugal), enrofloxacin
(ENR, Bayer, Germany), marbofloxacin (MAR, Vétoqui-
nol, France) and orbifloxacin (OBX, Schering-Plough,
USA) were determined by broth microdilution, following
Clinical and Laboratory Standards Institute guidelines
[14,15]. E. coli ATCC 25922 was used as a reference con-
trol for MIC testing. Dilution range for all antimicrobial
compounds tested was from 256 to 0.00003 μg/mL.
Biofilm production was tested by fluorescent in situ
hybridization, as previously described [16], in two broth
media, TSB (Tryptic Soy Broth, Oxoid, CM0129B) and
BHIB (Brain Heart Infusion Broth, Oxoid, CM0225),
using the universal bacterial probe, Eub338, labelled withfluorescein (Stabvida, Portugal). Wilcoxon signed ranks
test was applied for statistical purposes.
From the 66 UPEC dog isolates evaluated, 31 isolates
were biofilm-positive in BHIB at 24 hours, 51 at
48 hours, and 59 at 72 hours. In TSB, a higher number
of biofilm-producing isolates was observed at all incu-
bation times: 35 isolates at 24 hours; 52 at 48 hours;
62 at 72 hours.
No significant differences (P > 0.05) were found between
biofilm formation in the two culture media, but significant
differences were found between biofilm production between
24 and 48 hours, 48 and 72 hours, and 24 and 72 hours
(P < 0.05).
Association between biofilm formation in TSB at
24 hours and the presence of cnf1, hly, pap and sfa was
not significant (P > 0.05), whilst there was a significant
association between biofilm and afa and aer (P < 0.05)
(Table 1). Biofilm production was also associated to the
Table 2 Antimicrobial susceptibility to 2nd generation fluoroquinolones and its relation with biofilm production in 66
E. coli isolates from dogs with urinary infections
Fluoroquinolones
CIP ENR MAR OBX
Susceptibility criteria (μg/mL)a Susceptible; Resistant ≤ 1; ≥ 4 ≤ 0.5; ≥ 4 ≤ 1; ≥ 4 ≤ 1; ≥ 8
Susceptibility results Susceptible 57 (86.4%) 57 (86.4%) 57 (86.4%) 56 (84.8%)
Resistant 9 (13.6%) 9 (13.6%) 9 (13.6%) 10 (15.2%)
Relation with biofilm production P < 0.05 P < 0.05 P < 0.05 P < 0.05
aIsolates that were categorized as intermediate to the antimicrobial compounds were recorded as susceptible, since the bactericidal activity of these antimicrobials
depends of their in vivo concentration and quinolones are known to be concentrated from 100- to 300-fold within the urinary tract (Cohn and others 2003); CIP
Ciprofloxacin (CLSI 2014), ENR Enrofloxacin (CLSI 2013), MAR Marbofloxacin (CLSI 2013), OBX Orbifloxacin (CLSI 2013).
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blaSHV and ampC (P < 0.05) (Table 1).
Fluoroquinolones resistance is summarized in Table 2.
Resistance was found in 13.6% of the uropathogenic
isolates (n = 9) towards ciprofloxacin, enrofloxacin,
marbofloxacin and orbifloxacin. One additional isolate
was resistant to orbifloxacin. All E. coli isolates were
simultaneously resistant to all the fluoroquinolones
tested.
Biofilm formation has been described as an important
E. coli virulence factor in human UTI. In this study,
biofilm-forming ability of 66 UPEC dog isolates was
evaluated. Previous works showed that isolates ability to
form biofilm depends upon the medium used and time
of observation [16-19]. In our study, no differences were
found regarding biofilm production in BHIB and TSB.
Almost half of the isolates were able to form biofilm at
24 hours in both media, and this percentage significantly
increased with incubation time.
Association between biofilm and other virulence fac-
tors has already been studied [18]. In this work, biofilm
was not associated to toxin production (hly and cnfI),
or to filamentous adhesions involved in host specific
adhesion (sfa and pap). Nevertheless, associations be-
tween biofilm and afa and aer were significant. These
results may indicate that adhesive non-fimbrial adhesions
are important for the initial steps of biofilm formation and
that the aerotaxis receptor may be involved in the oxygen-
ation of these structures. Biofilm production was also
associated to the presence of the β-lactamase genes. Our
results are not in accordance with previous works [18,20]
that stated that E. coli strains that are β-lactamase pro-
ducers may not be able to form biofilms.
Regarding fluoroquinolones resistance, compounds
tested showed an in vitro efficacy of more than 80%, as
already observed by other authors [11,21]. It is import-
ant to refer that although these broad-spectrum antibi-
otics are extensively used for treatment of animal related
infections, their efficacy remains high [11].
Biofilm structures are believed to impair antimicrobial
compounds action [10,22]. Association between biofilmand fluoroquinolone resistance was considered signifi-
cant in all time points, independently of the media,
which is in agreement with previous human UTI studies
[9]. Biofilm formation by UPEC may contribute for UTI
treatment failure in dogs, since these structures are
responsible for the establishment of bacterial reservoirs
inside the bladder cells, allowing them to overcome the
host immune defences and to establish recurrent infec-
tions [9].
To our knowledge, this is the first report of the asso-
ciation between biofilm formation and fluoroquinolone
resistance in E. coli dog UTI isolates, representing an
important novelty. This fact is relevant for biofilm and
antimicrobial resistance control in veterinary medicine
and the establishment of more adequate therapeutic
protocols.
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